萬豐奧威(002085.SZ):通航飛機在全球擁有奧地利、加拿大、中國(青島、新昌)4個生產製造基地
格隆匯2月22日丨萬豐奧威(002085.SZ)在接受特定對象調研時表示,公司通航飛機創新制造產業已形成“技術研發-授權/技術轉讓-整機制造銷售-售後服務”經營模式,擁有10種基本型,18款機型的全部知識產權,產品涉及教練機、私人消費機、特殊用途MPP飛機,在全球擁有奧地利、加拿大、中國(青島、新昌)4個生產製造基地,年產能超三百架。
未來,公司一方面優化產品結構,提升高附加值消費及特殊用途機型佔比;另一方面通過開展授權/技術轉讓業務,提升鑽石飛機全球市場佔有率。同時對於國內市場,公司將通過引進新機型,卡位新基地,助力國內通航產業穩健發展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.